Clearmind Medicine (CMND) Cash & Equivalents (2021 - 2026)

Clearmind Medicine's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $11.4 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 155.24% year-over-year to $11.4 million; the TTM figure through Apr 2026 stood at $11.4 million (up 155.24% YoY), while the FY2025 annual figure was $3.9 million, down 40.32% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $11.4 million, up from $9.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $11.4 million in Q2 2026, with the low at $132334.9 in Q4 2022.
• The 5-year median for Cash & Equivalents is $5.3 million (2023), against an average of $5.7 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 96.38% in 2022, then surged 4001.52% in 2023.
• Clearmind Medicine's Cash & Equivalents stood at $132334.9 in 2022, then soared by 4001.52% to $5.4 million in 2023, then increased by 21.12% to $6.6 million in 2024, then tumbled by 40.32% to $3.9 million in 2025, then soared by 190.99% to $11.4 million in 2026.
• Business Quant data shows CMND's Cash & Equivalents at $11.4 million in Q2 2026, $9.3 million in Q1 2026, and $3.9 million in Q4 2025.